INNOCARE

9969
11.2702.93% ( -0.340 )
Delay Closed: Nov 16, 16:08:11

Overview

INNOCARE (9969)

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune d...

Open
11.600
High
11.750
Low
11.190
Prev. Close
11.610
Volume
4.63M
Turnover
52.32M
Avg Price
11.310
Bid/Ask Ratio
-83.33%
Amplitude
4.82%
52wk High
16.200
Volume Ratio
0.46
Turnover Ratio
0.31%
52wk Low
9.650
HK Mkt Cap
16.84B
Market CapHKD
19.92B
P/ETTM
12.55
P/EDynamic
19.56
P/EStatic
--
EPSTTM
0.898
EPSDynamic
0.576
EPSStatic
--
BVPS
5.40
P/B
2.09
HK Shares
1.49B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.77B
Min lot size
1,000
Currency
HKD

INNOCARE Analyst Rating

View more

Forecast & Rating

Nov 9, 2026
Price forecast
HK$18.1360.90%
Forecast & RatingStrong buy
11analysts
  • Strong buy81.82%
  • Buy18.18%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 4

    InnoCare rose 8.27% to HK$12.04, matching the session high and close, from HK$11.12, after the biotech index jumped nearly 8% in the afternoon on expectations that Democrats could control both houses of Congress; the stock moved almost one-way from the 09:30 low of HK$11.02, with HK$97.8 million turnover and a 0.56% turnover rate. The move had fundamental support: Q3 2026 revenue reached HK$1.13 billion, up 168% yoy, net profit HK$479 million, up 1,377%, net margin 42.5%, while the orelabrutinib combination showed an 89.5% objective response rate in a Phase 2 marginal zone lymphoma trial. CMBI and Goldman Sachs raised their target prices to HK$18.9 and HK$23.16 respectively. Even so, the close remains below MA60 of HK$13.76 and 25.7% below the 52-week high of HK$16.2, with a YTD decline of 3.68%, and it is still slightly under MA20 of HK$12.05.

  2. Oct, 28

    InnoCare opened lower but climbed steadily from HK$11.41 to HK$11.98 intraday and closed at HK$12.00, up 5.1%, as Q3 results and ESMO data landed together: quarterly revenue of HK$1.126bn rose 168% year on year, net profit of HK$479m jumped roughly 13.8x, net margin reached 42.5% and ROE 20.6%, while first-nine-month net profit attributable to shareholders of about RMB656m swung to a profit, and the orelabrutinib combination showed an 89.5% response rate in Phase 2 marginal zone lymphoma and won CDE clearance for a registrational Phase III, with Guotai Haitong initiating a Buy. Yet at HK$12.00 the stock still sits below its MA20 of 12.71 and MA60 of 13.98, 25.9% below the 52-week high of HK$16.20 set on 22 September, down 4% year to date, on 13.4x PE and 2.22x PB, while the controlling family's over HK$60m selldown in Q3 and the sector-wide slide on a peer's rights issue remain in memory.

  3. Oct, 27

    Profit-taking after the Q3 delivery left the stock down 1.64% at HK$11.42. It opened at HK$11.90, spiked to an intraday high of HK$11.94 in the morning session and then faded to HK$11.29 by 14:56 BJ time on turnover of about HK$95.9m, a classic spike-and-fade. Fundamentals contrast with the tape: Q3 revenue of HK$1.126bn rose 168.2% yoy, net profit of HK$478.9m jumped 1376.5% yoy with a 42.5% net margin, and nine-month attributable profit of about RMB656m reversed a year-earlier loss; orelabrutinib combinations showed a 100% preliminary response rate in Phase 2 MZL, the CDE cleared a registrational Phase III in r/r MZL, and Guotai Haitong assigned a Buy. The stock remains down 8.64% YTD, roughly 29.5% below its 52-week high of HK$16.20 and beneath its MA20 of 12.815 and MA60 of 14. Though a family stake sale of over RMB60m and a broader sector pullback add near-term noise.

  4. Oct, 22

    InnoCare slid about 6.5% to HK$11.75 on October 22 in a spike-and-fade session that opened at HK$12.31, touched HK$12.59 in the morning, then ground down to HK$11.67 late in the afternoon session on HK$72.6 million turnover, after Akeso's rights issue triggered a broad selloff across Hong Kong-listed biopharma names. Company-specific news flow was constructive: orelabrutinib combination therapy showed a 100% response rate in preliminary Phase 2 marginal zone lymphoma data, the CDE cleared a registrational Phase III in r/r MZL, and the TL1A/IL-23p19 bispecific antibody received clinical trial approval. Fundamentals still track ahead, with Q2 2026 revenue of HK$703 million up 83% year on year and net profit of HK$162 million up 408%, yet the shares remain below their MA20 of HK$13.30 and MA60 of HK$14.11, down 6% year to date and 27.5% below the 52-week high of HK$16.2 set on September 22. A board meeting to approve Q3 results is pending, though near-term direction still hinges on sector flows.

  5. Oct, 16

    InnoCare closed up 2.67% at HK$12.32 on a run of orelabrutinib news in marginal zone lymphoma: its combination showed a 100% response rate in preliminary Phase 2 r/r MZL results, mitoclax plus orelabrutinib won CDE clearance for a registrational Phase III in MZL, and three orelabrutinib studies were selected for oral sessions at the 88th Japanese Society of Hematology meeting, while the TL1A/IL-23p19 bispecific ICP-B161 also gained clinical trial approval. The session traced a spike-and-fade pattern, peaking at HK$12.62 at 11:09 BJ and dipping to HK$12.01 at 14:42 BJ before a modest recovery. Q2 2026 revenue reached HK$702.76m, up 83.15% yoy, with net profit of HK$162.33m up 408.25% and EPS of HK$0.0925. Still, the stock trades below its MA20 of 13.75 and MA60 of 14.19, sits 38.95% under the 52-week high of HK$20.18 and is down 1.44% year to date, with Q3 results pending board approval.

News

Bullish vs. Bearish — Last 3 Months

3.8k followers · 0 opinions
▲Bullish50%
50%Bearish▼